Moreno-Otero R, García-Monzón C, García-Sánchez A, García Buey L, Pajares J M, Di Bisceglie A M
Gastroenterology (Liver Unit) Service, Hospital de la Princesa, Universidad Autónoma, Madrid, Spain.
Am J Gastroenterol. 1991 May;86(5):560-4.
The rate of HBeAg clearance and the outcome were analyzed in 46 patients with asymptomatic chronic hepatitis B virus (HBV) infection whose condition was followed for 1-4 yr (mean 2.4). Mean age was 32.5 yr (range 10-68), and 28 (61%) were males. All had chronic hepatitis, on biopsy, and were positive for HBcAg on hepatocytes. Alcoholics, homosexuals, drug abusers, immunocompromised patients, and those with advanced liver disease were excluded. During the follow-up, 25 patients (54%) cleared HBeAg and became seronegative for HBV-DNAp. The estimated annual rate of seroconversion was 26%. One patient cleared HBsAg. After seroconversion, 18 patients had no evidence of ongoing liver disease, proved by biopsy in eight and by clinical follow-up in 10 that refused biopsy. A second liver biopsy was available in 15 patients, and HBcAg was negative in all; histology was normal in eight, unchanged in one, and compatible with cirrhosis in six. All six had clinical and/or biochemical evidence of advanced liver disease. These were significantly older at the start of the study, and had chronic active hepatitis with bridging necrosis on initial biopsy. Early identification of patients with silent chronic HBV infection and high levels of viral replication for antiviral therapy could prevent transmission of the infection and stop progression to liver cirrhosis and hepatocellular carcinoma.
对46例无症状慢性乙型肝炎病毒(HBV)感染患者的HBeAg清除率和转归进行了分析,这些患者的病情随访了1至4年(平均2.4年)。平均年龄为32.5岁(范围10至68岁),男性28例(61%)。所有患者经活检均患有慢性肝炎,肝细胞HBcAg均为阳性。排除酗酒者、同性恋者、药物滥用者、免疫功能低下患者以及晚期肝病患者。随访期间,25例患者(54%)清除了HBeAg,HBV-DNAp转为血清学阴性。估计血清学转换的年发生率为26%。1例患者清除了HBsAg。血清学转换后,18例患者无持续肝病证据,8例经活检证实,10例拒绝活检者经临床随访证实。15例患者可进行第二次肝活检,所有患者的HBcAg均为阴性;8例组织学正常,1例无变化,6例符合肝硬化。所有6例均有晚期肝病的临床和/或生化证据。这些患者在研究开始时年龄显著较大,初次活检时有慢性活动性肝炎伴桥接坏死。早期识别无症状慢性HBV感染且病毒复制水平高的患者进行抗病毒治疗,可预防感染传播并阻止进展为肝硬化和肝细胞癌。